- Home
- LNG vs EW Comparison
LNG vs EW Comparison
Compare LNG & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNG
- EW
- Stock Information
- Founded
- LNG 1983
- EW 1958
- Country
- LNG United States
- EW United States
- Employees
- LNG N/A
- EW N/A
- Industry
- LNG Oil/Gas Transmission
- EW Industrial Specialties
- Sector
- LNG Utilities
- EW Health Care
- Exchange
- LNG Nasdaq
- EW Nasdaq
- Market Cap
- LNG 52.1B
- EW 44.8B
- IPO Year
- LNG 1997
- EW 2000
- Fundamental
- Price
- LNG $235.69
- EW $80.92
- Analyst Decision
- LNG Strong Buy
- EW Buy
- Analyst Count
- LNG 13
- EW 20
- Target Price
- LNG $262.77
- EW $85.20
- AVG Volume (30 Days)
- LNG 1.6M
- EW 3.6M
- Earning Date
- LNG 10-30-2025
- EW 10-23-2025
- Dividend Yield
- LNG 0.85%
- EW N/A
- EPS Growth
- LNG N/A
- EW 188.09
- EPS
- LNG 17.11
- EW 7.02
- Revenue
- LNG $18,231,000,000.00
- EW $5,685,100,000.00
- Revenue This Year
- LNG $33.66
- EW $13.25
- Revenue Next Year
- LNG $12.70
- EW $9.76
- P/E Ratio
- LNG $13.77
- EW $11.52
- Revenue Growth
- LNG 14.42
- EW 9.14
- 52 Week Low
- LNG $175.14
- EW $64.01
- 52 Week High
- LNG $257.65
- EW $83.00
- Technical
- Relative Strength Index (RSI)
- LNG 48.16
- EW 56.62
- Support Level
- LNG $239.29
- EW $80.08
- Resistance Level
- LNG $243.50
- EW $82.67
- Average True Range (ATR)
- LNG 4.51
- EW 1.39
- MACD
- LNG -0.08
- EW -0.01
- Stochastic Oscillator
- LNG 45.26
- EW 65.04
About LNG Cheniere Energy Inc.
Cheniere Energy is a liquified natural gas, or LNG, producer with two facilities in Corpus Christi, Texas and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed and variable fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.